Topic: JPM 2019

Attendees fed up with venue, prices call to move JPM out of SF

by Conor Hale

Tuesday, January 15, 2019

While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there are becoming untenable for some.

by Amirah Al Idrus

Friday, January 11, 2019

Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.

by Amirah Al Idrus

Friday, January 11, 2019

Armed with a total of $375 million raised, Orchard will build its own manufacturing site in California, to start running in 2021.

by Amirah Al Idrus, Conor Hale, Ben Adams

Friday, January 11, 2019

What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.

by Conor Hale

Thursday, January 10, 2019

At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.

by Amirah Al Idrus

Thursday, January 10, 2019

The FDA shutdown is holding up human trials for Aimmune's egg allergy program and may delay approval for its oral immunotherapy for peanut allergy.

by Ben Adams

Wednesday, January 9, 2019

We certainly like to offer a full breakfast here at FierceBiotech, especially at the J.P. Morgan Healthcare Conference here in San Francisco.

by Amirah Al Idrus

Wednesday, January 9, 2019

Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.

by Amirah Al Idrus

Wednesday, January 9, 2019

In 2019, Tmunity hopes to share data from its lead T cell programs and announce new solid tumor targets.

by Conor Hale

Wednesday, January 9, 2019

Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.